Src inhibitors in lung cancer: current status and future directions.
about
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancersWrangling phosphoproteomic data to elucidate cancer signaling pathwaysRegulation of SRC family kinases in human cancersAn update on dual Src/Abl inhibitors.Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.Src family kinases and paclitaxel sensitivity.miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC.Control of asymmetric Hopfield networks and application to cancer attractorsDigoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung CancerTargeting invadopodia to block breast cancer metastasisRhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In VivoMicroRNAs as the fine-tuners of Src oncogenic signalling.Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis.HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.[Effects of Src on proliferation and invasion of lung cancer cells].YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.
P2860
Q24303562-30F1420F-8950-48A1-A4F3-78717AD6627AQ27323958-31BE4E40-E842-4F2E-AEDF-E783F14D08ECQ28243770-ACA75BD9-4739-423C-8B62-8464A594AD79Q34270677-FE61167B-8959-499C-813C-EA8F4DBA4D1FQ34657670-C0C42B69-7AAF-4181-A378-ED9190867AA0Q35214722-11084823-CE5C-4F3F-9DBB-D09B803C4BA3Q35228579-7B943AC7-F75E-45A1-9DBF-E183825F4133Q35234867-ABB8BA0F-70A6-47EB-9ABA-2897983D33E6Q35587056-B46684F0-5E6E-45D4-AB0C-BEA4BD490A07Q35640216-F8179F74-445F-4276-B8E2-353B0650F166Q36413425-370A42D7-B313-48B1-A745-B9E4C814A469Q36832243-7E61CA6A-0A9B-4F8B-AFD5-45BCDF1CA164Q38415772-B225299F-2F17-4AD0-832B-75F33D160555Q38893460-D3EF6E21-853A-47A8-B230-8ADD1B61CCBAQ39411400-E6A57317-919A-4DA2-89EA-30B52485FB95Q42380691-9F6A41C5-FDF7-4936-9689-8D0CCB839C14Q46666843-6AD6E7DD-5389-43A8-9536-BF06EE00A7CCQ47214772-647474F5-951E-43DF-8937-17EAE17A40E7Q53287912-45AE7C46-44E9-45DE-9D08-505E4EF5429CQ53686708-746628AB-2512-4C69-9AE9-12F709859AA3Q54485558-A351FAF8-9BC6-423A-897B-D963F2026B34Q55280808-76217CB9-2F70-4A7B-84A2-77D5F107C54F
P2860
Src inhibitors in lung cancer: current status and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Src inhibitors in lung cancer: current status and future directions.
@en
Src inhibitors in lung cancer: current status and future directions.
@nl
type
label
Src inhibitors in lung cancer: current status and future directions.
@en
Src inhibitors in lung cancer: current status and future directions.
@nl
prefLabel
Src inhibitors in lung cancer: current status and future directions.
@en
Src inhibitors in lung cancer: current status and future directions.
@nl
P2093
P356
P1433
P1476
Src inhibitors in lung cancer: current status and future directions.
@en
P2093
Eric B Haura
Faye M Johnson
Oliver Gautschi
Sacha I Rothschild
P304
P356
10.3816/CLC.2010.N.030
P407
P577
2010-07-01T00:00:00Z